European Commission Approves Six Additional Indications for Merck’s Keytruda

The European Commission has approved Merck’s blockbuster oncology drug Keytruda (pembrolizumab) for six new indications, including persistent, recurrent or metastatic cervical cancer.
Source: Drug Industry Daily